Theranostics: integrating molecular imaging and targeted therapy for precision medicine across oncology and beyond

Sanjeyan N.; Yuvaraj C.; Naveen Kumar S.; Balakrishnan S.; Suban M.

doi:10.18203/2320-6012.ijrms20263578

Authors

Sanjeyan N. Department of Pharmacy Practice, JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Yuvaraj C. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Naveen Kumar S. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Balakrishnan S. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Suban M. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263578

Keywords:

Theranostics, Precision medicine, Radiotheranostics, Nanotheranostics, Phototheranostics, PET imaging

Abstract

To review the principles, mechanisms, clinical applications, safety considerations, challenges and future perspectives of theranostics. Literature from peer-reviewed journals, clinical trials and authoritative sources was reviewed. Theranostics integrates molecular imaging and targeted therapy, demonstrating significant benefits in neuroendocrine tumors, prostate cancer, lymphoma and emerging non-oncologic diseases. Theranostics represents a cornerstone of precision medicine and is expected to expand further with advances in artificial intelligence, nanotechnology and novel radiopharmaceuticals.

Metrics

Metrics Loading ...

References

Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discov. 2002;2(2):17-9.

Hertz S, Roberts A, Salter WT. Radioactive iodine as an indicator in thyroid physiology: IV. The metabolism of iodine in Graves' disease. J Clin Invest. 1942;21(1):25-9.

Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132(14):838-47.

Ehrhardt JD Jr, Güleç S. A review of the history of radioactive iodine theranostics: the origin of nuclear oncology. Mol Imaging Radionucl Ther. 2020;29(3):88-97.

Goldsmith SJ. History of 131I therapy. J Nucl Med. 2012;53(11):1839-40.

Bodei L, Iagaru A, Schmidt A, Herrmann K. Theranostics in oncology: from molecular imaging to precision medicine. Eur J Nucl Med Mol Imaging. 2020;47(Suppl 1):1-4.

Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879-903.

Lameijer MAM, Dierckx RAJO, de Vries EGE, Lub-de Hooge MN. Molecular nuclear medicine: the future of molecular imaging and targeted therapy. Lancet Oncol. 2020;21(3):e130-43.

Vikram R, Johnson CB, Kwee TC. Theranostics: a primer for medical students and residents. Semin Nucl Med. 2023;53(4):475-84.

Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-ay M, Javadi MS, et al. Prospective evaluation of 68Ga-PSMA-11 PET/CT for preoperative staging of intermediate- to high-risk prostate cancer. Eur Urol. 2018;73(2):315-6.

Weber WA, Czernin J. From nuclear medicine to theranostics: the long road to precision oncology. J Nucl Med. 2021;62(Suppl 1):17S-22S.

Herrmann K, Larson SM, Weber WA. Theranostics: an overview from concept to clinical implementation. J Nucl Med. 2021;62(Suppl 1):1S-6S.

Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, et al. Guiding principles on the education and practice of theranostics. Eur J Nucl Med Mol Imaging. 2024;51(8):2320-31.

Lee DY, Li KC. Advanced theranostics for personalized medicine. Invest Radiol. 2011;46(7):438-46.

Sedlack AJH, Meyer C, Mench A, Winters C, Barbon D, Obrzut S, et al. Essentials of theranostics: a guide for physicians and medical physicists. RadioGraphics. 2024;44(1):e230097.

Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, et al. Theranostics in nuclear medicine practice. Onco Targets Ther. 2017;10:4821-8.

Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, et al. Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720-34.

Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoğlu K, et al. A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer. 2023;5(4):e220157.

Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in oncology: current challenges and emerging opportunities. EMBO Mol Med. 2024;16(2):237-52.

Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and SPECT/CT. Cancer Imaging. 2014;14(1):33.

Kelkar SS, Reineke TM. Nanomaterials in macromolecular therapeutics and theranostics. In: Davis ME, editor. Comprehensive Biomaterials. Elsevier; 2011. p. 513-31.

Hapuarachchige S, Artemov D. Theranostic pretargeting drug delivery and imaging platforms in cancer precision medicine. Front Oncol. 2020;10:1131.

Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):623-30.

Vinjamuri S, Gilbert TM, Banks M, Shannon G, Hall N, Frank J, et al. Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013;108(7):1440-8.

Choy JS, Sharma R, Seshadri M, Green MC. Incidental uptake of 111In-ibritumomab tiuxetan in surgically treated fracture. Open Med Imaging J. 2010;4:132-4.

Pantel AR, Eiber M, Beyder DD, Bozkurt MF, Bural GG, Baum RP, et al. SNMMI procedure standard/EANM practice guideline for palliative nuclear medicine therapies of bone metastases. J Nucl Med Technol. 2023;51(3):176-87.

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-103.

Assadi M. Emerging preclinical and clinical applications of theranostics. Semin Nucl Med. 2021;51(4):297-304.

Goyal AK, Ramchandani M, Basak T. Recent advancements, challenges, and future prospects in usage of nanoformulation as theranostics in inflammatory diseases. J Nanotheranostics. 2023;4(1):106-26.

Li L, Yin Y, Zhang S, Zhang H, Zhang P, Li Y, et al. Triggerable biomaterials-based osteomyelitis theranostics. BMEMat. 2024;2(4):e12081.

Cicone F, Gnesin S, Santo G, Stokke C, Bartolomei M, Cascini GL, et al. Do we need dosimetry for the optimization of theranostics in CNS tumors? Neuro-Oncology. 2024;26(Suppl 9):S242-58.

Bednarz B. Theranostics and patient-specific dosimetry. Semin Radiat Oncol. 2023;33(3):317-26.

Miller C, Rousseau J, Ramogida CF. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics. 2022;12(1):232-59.

Al-Ibraheem A. Theranostics in developing countries: addressing challenges and potentials from training to practice. World J Nucl Med. 2023;22(2):83-8.

Brink A, Sathekge MM. Global challenges in the provision of theranostic services. Radiol Imaging Cancer. 2024;6(2):e230182.

Currie GM, Wheat JM. Molecular theranostics: principles, challenges, and controversies. J Med Radiat Sci. 2024;71(2):221-32.

Pathmaraj K, Lee ST. Approaches to conducting clinical trials in theranostics. Clin Transl Radiat Oncol. 2024;46:100774.

Trpezanovski M, Bailey DL, Willowson KP. Dosimetry in radionuclide therapy: an essential component of clinical trials. Clin Transl Imaging. 2023;11(4):325-37.

Singh D, Sharma R, Sharma S, Negi R, Bisht P. Smart nanomaterials in cancer theranostics: challenges and opportunities. ACS Omega. 2023;8(25):22340-55.

Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Pesquero JB, et al. Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. RadioGraphics. 2020;40(6):1715-40.

Bilgin GB, Al-Nahhas A. Current and future directions in theranostics: from oncology to non-oncology applications. Semin Nucl Med. 2024;54(4):450-62.

Pathmaraj K, Lee ST. Multidisciplinary perspectives of clinical trials in theranostics. World J Nucl Med. 2024;23(1):14-22.

Herrmann K, Schwaiger M, Lewis JS, Solomon SB, Zheng J, Fleming IN, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21(3):e146-56.

Chen X, Gambhir SS, Cheon J. Theranostics: past, present, and future perspectives. Theranostics. 2023;13(15):5559-66.